Drug Trial Radar · NCT00966914
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Last checked: Nov 19, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
Apr 2010
Primary completion
Apr 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- BioNumerik Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.
- First posted
- Aug 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tavocept is an investigational drug that is being developed to see if it can increase the survival of patients who are being treated with chemotherapy as well as to see if it can prevent or reduce side effects of chemotherapy. This research study is aimed at trying to find out if people with advanced adenocarcinoma of the lung who are treated with a standard combination of chemotherapy drugs will live longer if they are also treated with an investigational drug called "Tavocept." Another objective of this research study is to find out whether or not Tavocept helps to prevent or reduce side-effects like kidney damage, anemia, and nausea and vomiting that can occur with these drug combinations. The drug combinations that will be used in this research study will include either paclitaxel and cisplatin, or docetaxel and cisplatin. These drug combinations are approved to be used to treat people with advanced NSCLC. Every patient on this research study will be treated with standard chemotherapy for primary NSCLC in the form of either docetaxel or paclitaxel (these will be recommended by your research study doctor), which will be given in combination with cisplatin.
Conditions
- Non-small Cell Lung Cancer
Interventions
Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxelDrug
Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
Placebo in combination with cisplatin and docetaxel or paclitaxelDrug
Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: throughout study
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Columbia, Missouri
Site not named
Philadelphia, Pennsylvania
Site not named
Germantown, Tennessee
Site not named
Gabrovo, Bulgaria
Site not named
Plovidv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Veliko Tarnovo, Bulgaria
Site not named
Elblag, Poland
Site not named
Szczecin, Poland
Site not named
Torun, Poland
Site not named
Warsaw, Poland
Site not named
Brasov, Romania
Site not named
Bucharest, Romania
Site not named
Cluj-Napoca, Romania
Site not named
Craiova, Romania
Site not named
Timișoara, Romania
Site not named
Arkangelsk, Russia
Site not named
Chelyabinsk, Russia
Site not named
Krasnodar, Russia
Site not named
Krasnodar Krai, Russia
Site not named
Kursk, Russia
Site not named
Moscow, Russia
Site not named
Novosibirsk, Russia
Site not named
Omsk, Russia
Site not named
Saint Petersburg, Russia
Site not named
Saint Petersburg, Russia
Site not named
Stavropol, Russia
Site not named
Stavropol Krai, Russia
Site not named
Tambov, Russia
Site not named
Voronezh, Russia
Site not named
Yaroslavl, Russia
Site not named
Yekaterinburg, Russia
Site not named
Chernihiv, Ukraine
Site not named
Dnipropetrovsk, Ukraine
Site not named
Donetsk, Ukraine
Site not named
Kharkiv, Ukraine
Site not named
Kherson, Ukraine
Site not named
Sumy, Ukraine
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.